ThePrint on MSN2d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the ...
Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...
Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...
Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback